Shire acquires PD compound

Shire (LSE:SHP; SHPGY) received exclusive worldwide rights from DevCo Pharmaceuticals (Guildford, U.K.) to develop and market a serotonin, dopamine and noradrenaline reuptake inhibitor. The product, w...